Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
002399.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.59B
Close$
$8.88
4.8% downside
Current Fair Value
4.8% downsideOvervalued by 4.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.59 Billion |
|---|---|
| Enterprise Value | $15.22 Billion |
| Dividend Yield | $0.14 (1.47%) |
| Earnings per Share | $0.24 |
| Beta | 0.31 |
| Outstanding Shares | 1,467,296,204 |
Return
| Return on Equity | 1.70% |
|---|---|
| Return on Assets | 1.23% |
| Return on Invested Capital | 2.36% |
Valuation & Multiples
| P/E Ratio | 70.85 |
|---|---|
| PEG | -105.84 |
| Price to Sales | 3.11 |
| Price to Book Ratio | 1.17 |
| Enterprise Value to Revenue | 2.9 |
| Enterprise Value to EBIT | 51.54 |
| Enterprise Value to Net Income | 74 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$1.40 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$2.56 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
2,150 employees
CEO: Li Li Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is an international pharmaceutical enterprise specializing in the production and commercialization of medicinal products. Its operations span Hong Kong, the United States, Europe, Mainland...